跳到正文
原文
Adam Feuerstein ✡️· @adamfeuerstein · X·· 22 天前精选AI 评分60
AI 导读

米兰讨论者 Monica Niger 在 ESMO26 上表示,Incyte 靶向 KRAS G12D 的胰腺癌药物与化疗联用的疗效和持久性很高,但胃肠道毒性高于预期,可能需要管理。Incyte 称该药可诱导持久的肿瘤缓解。

推荐理由

ESMO26 讨论者既肯定该 KRAS G12D 抑制剂联合化疗的疗效与持久性,也指出胃肠道毒性高于预期,呈现获益与风险的权衡。

正文

Updated: Discussant Monica Niger of Milan said the Incyte-chemo combination efficacy and durability was very high, but she also noted higher than expected GI toxicity that may need to be managed. $INCY #ESMO26

引用Adam Feuerstein ✡️@adamfeuerstein
Incyte $INCY pancreatic cancer drug— it targets KRAS G12D -- induces lasting tumor responses, company says at #ESMO26 https://www.statnews.com/2026/10/26/incyte-esmo-pancreatic-cancer-incb161734-results/
在 X 查看被引用的帖子

来源:Adam Feuerstein ✡️ · x.com